Skip to main content

Research Repository

Advanced Search

All Outputs (12)

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease (2023)
Journal Article
Munir, T., Cairns, D. A., Bloor, A., Allsup, D., Cwynarski, K., Pettitt, A., Paneesha, S., Fox, C. P., Eyre, T. A., Forconi, F., Elmusharaf, N., Kennedy, B., Gribben, J., Pemberton, N., Sheehy, O., Preston, G., Schuh, A., Walewska, R., Duley, L., Howard, D., …Hillmen, P. (2024). Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine, 390(4), 326-337. https://doi.org/10.1056/NEJMoa2310063

BACKGROUND: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment duration... Read More about Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials (2023)
Journal Article
Molica, S., & Allsup, D. (2023). Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials. Expert Review of Anticancer Therapy, https://doi.org/10.1080/14737140.2023.2288899

Introduction: Chronic lymphocytic leukemia (CLL) management has witnessed a transformative shift with the advent of time-limited venetoclax and anti-CD20 monoclonal antibody (mAb) regimens, as exemplified by the groundbreaking MURANO and CLL14 trials... Read More about Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials.

Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions (2023)
Journal Article
Molica, S., Tam, C., Allsup, D., & Polliack, A. (in press). Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions. Hematological Oncology, https://doi.org/10.1002/hon.3238

In the modern era of Chronic Lymphocytic Leukemia (CLL) targeted therapy, the loss of p53 function due to genetic abnormalities remains a significant challenge. This is because even targeted agents, which are currently the mainstay of treatment for C... Read More about Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.

Early Human Pathophysiological Responses to Exertional Hypobaric Decompression Stress (2023)
Journal Article
Connolly, D., Madden, L. A., Edwards, V., D'Oyly, T., Harridge, S., Smith, T., & Lee, V. (2023). Early Human Pathophysiological Responses to Exertional Hypobaric Decompression Stress. Aerospace Medicine and Human Performance, 94(10), 738-749. https://doi.org/10.3357/AMHP.6247.2023

INTRODUCTION: Consistent blood biomarkers of hypobaric (altitude) decompression stress remain elusive. Recent laboratory investigation of decompression sickness risk at 25,000 ft (7620 m) enabled evaluation of early pathophysiological responses to ex... Read More about Early Human Pathophysiological Responses to Exertional Hypobaric Decompression Stress.

In preprints: opportunities to unravel the earliest stages of human development using stem cell-based embryo models (2023)
Journal Article
Moris, N., & Sturmey, R. (2023). In preprints: opportunities to unravel the earliest stages of human development using stem cell-based embryo models. Development, 150(17), Article dev202295. https://doi.org/10.1242/dev.202295

Several exciting advances have enabled the derivation of stem cell-based embryo-like models (SCBEMs). Such models allow us to interrogate previously intractable questions in developmental biology and ask hypothesis-driven fundamental questions such a... Read More about In preprints: opportunities to unravel the earliest stages of human development using stem cell-based embryo models.

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option (2023)
Journal Article
Molica, S., Tam, C., Allsup, D., & Polliack, A. (2023). Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option. Cancers, 15(14), Article 3737. https://doi.org/10.3390/cancers15143737

Ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor (BTKi), is a commonly deployed therapeutic option for previously untreated and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia (CLL). The use of ibrutinib is, howev... Read More about Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option.

A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells (2023)
Journal Article
Guinn, B. A., Schuler, P. J., Schrezenmeier, H., Hofmann, S., Weiss, J., Bulach, C., …Greiner, J. (2023). A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells. International Journal of Molecular Sciences, 24(11), Article 9285. https://doi.org/10.3390/ijms24119285

Immune checkpoint inhibitors can block inhibitory molecules on the surface of T cells, switching them from an exhausted to an active state. One of these inhibitory immune checkpoints, programmed cell death protein 1 (PD-1) is expressed on T cell subp... Read More about A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial (2023)
Journal Article
Hillmen, P., Pitchford, A., Bloor, A., Broom, A., Young, M., Kennedy, B., Walewska, R., Furtado, M., Preston, G., Neilson, J. R., Pemberton, N., Sidra, G., Morley, N., Cwynarski, K., Schuh, A., Forconi, F., Elmusharaf, N., Paneesha, S., Fox, C. P., Howard, D. R., …Munir, T. (2023). Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The lancet oncology, 24(5), 535-552. https://doi.org/10.1016/S1470-2045%2823%2900144-4

Background: The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients considered unfit for fludara... Read More about Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol (2023)
Journal Article
Baldwin, Z.-A., Busby, S., Allsup, D., Cohen, J., & Bamidele, O. (2023). Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol. PLoS ONE, 18(3), Article e0282458. https://doi.org/10.1371/journal.pone.0282458

Introduction Haematological malignancies are a heterogenous group of blood and lymphatic cancers. Survivorship care is a similarly diverse term concerning patients’ health and wellbeing from diagnosis to end of life. Survivorship care for patients wi... Read More about Provision and delivery of survivorship care for adult patients with haematological malignancies: A scoping review protocol.

Detection of microplastics in human saphenous vein tissue using μFTIR: a pilot study (2023)
Journal Article
Rotchell, J. M., Jenner, L. C., Chapman, E., Bennett, R., Bolanle, I. O., Loubani, M., Sadofsky, L., & Palmer, T. (2023). Detection of microplastics in human saphenous vein tissue using μFTIR: a pilot study. PLoS ONE, 18(2), Article e0280594. https://doi.org/10.1371/journal.pone.0280594

Microplastics (MPs) are ubiquitous in the environment, in the human food chain, and have been recently detected in blood and lung tissues. To undertake a pilot analysis of MP contamination in human vein tissue samples with respect to their presence (... Read More about Detection of microplastics in human saphenous vein tissue using μFTIR: a pilot study.

Multi-dimensional experimental and computational exploration of metabolism pinpoints complex probiotic interactions (2023)
Journal Article
Zampieri, G., Efthimiou, G., & Angione, C. (2023). Multi-dimensional experimental and computational exploration of metabolism pinpoints complex probiotic interactions. Metabolic Engineering, 76, 120-132. https://doi.org/10.1016/j.ymben.2023.01.008

Multi-strain probiotics are widely regarded as effective products for improving gut microbiota stability and host health, providing advantages over single-strain probiotics. However, in general, it is unclear to what extent different strains would co... Read More about Multi-dimensional experimental and computational exploration of metabolism pinpoints complex probiotic interactions.